JP2006528952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528952A5 JP2006528952A5 JP2006529883A JP2006529883A JP2006528952A5 JP 2006528952 A5 JP2006528952 A5 JP 2006528952A5 JP 2006529883 A JP2006529883 A JP 2006529883A JP 2006529883 A JP2006529883 A JP 2006529883A JP 2006528952 A5 JP2006528952 A5 JP 2006528952A5
- Authority
- JP
- Japan
- Prior art keywords
- dna
- propenamide
- indol
- hydroxyethyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 229940009456 Adriamycin Drugs 0.000 description 3
- 229960004679 Doxorubicin Drugs 0.000 description 3
- BWDQBBCUWLSASG-MDZDMXLPSA-N (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 210000003483 Chromatin Anatomy 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000002112 DNA intercalation Effects 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001335 demethylating Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
Description
一般的に言うと、本発明の組み合わせに有用な化学療法剤は、すなわち、上記の任意の化学療法剤、およびとりわけＤＮＡトポイソメラーゼII阻害剤、微小管活性化剤、チミジン産生阻害剤、ＤＮＡトポイソメラーゼＩ阻害剤、およびＤＮＡ脱メチル化剤を、ＨＤＡＩ化合物と共に、各薬剤単独の治療の通常の経過で用いられる通りの投与量および治療レジメンで使用し得る。
適当であれば、非置換は置換基がないかまたは唯一の置換基が水素であることを意味する。
細胞を、Ｎ−ヒドロキシ−３−[４−[[(２−ヒドロキシエチル)[２−(１Ｈ−インドール−３−イル)エチル]−アミノ]メチル]フェニル]−２Ｅ−２−プロペンアミドの２４時間前にアドリアマイシンで処置したとき、相乗効果が得られる。
ＭＤＡ−ＭＢ−４３５Ｐ細胞をアドリアマイシンで前処置し、続いてＮ−ヒドロキシ−３−[４−[[(２−ヒドロキシエチル)[２−(１Ｈ−インドール−３−イル)エチル]−アミノ]メチル]フェニル]−２Ｅ−２−プロペンアミドで処置したときに観察される相乗効果の基礎は現在まだ判らない。しかしながら、Ｎ−ヒドロキシ−３−[４−[[(２−ヒドロキシエチル)[２−(１Ｈ−インドール−３−イル)エチル]−アミノ]メチル]フェニル]−２Ｅ−２−プロペンアミドによりクロマチン構造の不安定化がＤＮＡインターカレーションにより悪化し、そしてアドリアマイシンによりＤＮＡ傷害が挿入される状況が予測できる。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47216103P | 2003-05-21 | 2003-05-21 | |
| PCT/EP2004/005433 WO2004103358A2 (en) | 2003-05-21 | 2004-05-19 | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006528952A JP2006528952A (ja) | 2006-12-28 |
| JP2006528952A5 true JP2006528952A5 (ja) | 2007-06-14 |
Family
ID=33476930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006529883A Pending JP2006528952A (ja) | 2003-05-21 | 2004-05-19 | ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070123580A1 (ja) |
| EP (1) | EP1628651A2 (ja) |
| JP (1) | JP2006528952A (ja) |
| CN (1) | CN1791396A (ja) |
| AU (1) | AU2004241729A1 (ja) |
| BR (1) | BRPI0410648A (ja) |
| CA (1) | CA2526908A1 (ja) |
| MX (1) | MXPA05012464A (ja) |
| WO (1) | WO2004103358A2 (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007501774A (ja) * | 2003-08-08 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | スタウロスポリンを含む組み合わせ |
| DE602004027824D1 (de) * | 2003-09-25 | 2010-08-05 | Astellas Pharma Inc | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer |
| ITRM20040288A1 (it) * | 2004-06-11 | 2004-09-11 | Sigma Tau Ind Farmaceuti | Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero. |
| KR101367516B1 (ko) | 2004-12-15 | 2014-02-27 | 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이. | 암치료용 치료제의 조합물 |
| NZ599464A (en) * | 2005-02-03 | 2014-03-28 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors |
| DK1901729T3 (da) | 2005-05-13 | 2012-05-14 | Topotarget Uk Ltd | Farmaceutiske formuleringer af HDAC-inhibitorer |
| AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| HUE028025T2 (en) * | 2005-08-03 | 2016-11-28 | Novartis Ag | Use of Panobinostat HDAC inhibitor to treat myeloma |
| CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| RU2452492C2 (ru) * | 2006-04-05 | 2012-06-10 | Новартис Аг | КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА |
| AU2007234379A1 (en) * | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| CN102584673B (zh) | 2006-06-12 | 2014-08-06 | 诺华股份有限公司 | N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的多晶型物 |
| EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER |
| JP2010509370A (ja) * | 2006-11-10 | 2010-03-25 | シンダックス ファーマシューティカルズ，インク． | 癌の治療用のＥＲα＋リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ |
| AU2007328281B2 (en) * | 2006-12-04 | 2011-03-31 | Novartis Ag | Combination of an HDAC inhibitor and an antimetabolite |
| EP2491923A3 (en) * | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| WO2008135786A1 (en) * | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer |
| EP2167090A4 (en) * | 2007-06-06 | 2010-08-25 | Univ Maryland | HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS |
| WO2009015203A1 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| US20100267779A1 (en) * | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| MX2010003230A (es) | 2007-09-25 | 2010-04-07 | Topotarget Uk Ltd | Metodos para la sintesis de ciertos compuestos de acido hidroxamico. |
| WO2009058895A1 (en) * | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| WO2009089598A2 (en) * | 2008-01-18 | 2009-07-23 | Katholieke Universiteit Leuven | Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer |
| US20110021517A1 (en) * | 2008-02-26 | 2011-01-27 | Nerviano Medical Sciences S.R.L. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| WO2009108857A2 (en) * | 2008-02-27 | 2009-09-03 | Combithera, Inc. | Combination therapy for prostate cancer |
| CN102441167B (zh) * | 2010-10-12 | 2014-05-07 | 鼎泓国际投资（香港）有限公司 | 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| WO2012096832A2 (en) * | 2011-01-12 | 2012-07-19 | Crystal Biopharmaceutical Llc | Hdac inhibiting derivatives of camptothecin |
| WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| EP1231919B1 (en) * | 1999-09-08 | 2015-09-30 | Sloan-Kettering Institute For Cancer Research | Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| BR0213932A (pt) * | 2001-11-06 | 2004-08-31 | Novartis Ag | Combinação do inibidor da ciclooxigenase-2/inibidor da desacetilase histona |
-
2004
- 2004-05-19 WO PCT/EP2004/005433 patent/WO2004103358A2/en not_active Application Discontinuation
- 2004-05-19 MX MXPA05012464A patent/MXPA05012464A/es unknown
- 2004-05-19 CA CA002526908A patent/CA2526908A1/en not_active Abandoned
- 2004-05-19 BR BRPI0410648-2A patent/BRPI0410648A/pt not_active IP Right Cessation
- 2004-05-19 AU AU2004241729A patent/AU2004241729A1/en not_active Abandoned
- 2004-05-19 EP EP04733798A patent/EP1628651A2/en not_active Withdrawn
- 2004-05-19 CN CNA2004800132382A patent/CN1791396A/zh active Pending
- 2004-05-19 JP JP2006529883A patent/JP2006528952A/ja active Pending
- 2004-05-19 US US10/557,162 patent/US20070123580A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006528952A5 (ja) | ||
| EA201391705A1 (ru) | Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i | |
| IL199673A0 (en) | 5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes | |
| WO2007100895A3 (en) | Cancer treatment with gamma-secretase inhibitors | |
| NZ590727A (en) | Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity | |
| TW200722421A (en) | Azole derivatives as inhibitors of lipases and phospholipases | |
| IL236518A0 (en) | Compounds of active 4,2,1-oxadiazole for oral administration for the treatment of suppression of nonsense mutation | |
| WO2009156735A3 (en) | New therapeutic agents | |
| DK1751108T3 (da) | Adamantyl-acetamidderivater som inhibitorer for 11-beta-hydroxysteroid-dehydrogenase-type 1-enzymet | |
| MX2009001327A (es) | Compuestos de indol. | |
| HK1134087A1 (en) | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| MX2009013332A (es) | Inhibidores de ire-1 alfa. | |
| HRP20141007T1 (en) | Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes | |
| MX2007003546A (es) | Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. | |
| TNSN08178A1 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| MX2007004699A (es) | Derivados de indol y bencimidazol. | |
| AU2002302587A1 (en) | Acne treatment with lipooxigenase inhibitors | |
| MX2009002735A (es) | Derivados de oxindol como agentes anticancerigenos. | |
| TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
| WO2006113261A3 (en) | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i | |
| EA200970161A1 (ru) | Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt | |
| NZ599464A (en) | Combination therapies using hdac inhibitors | |
| EP2452935A3 (en) | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| WO2008057780A3 (en) | Transdermal delivery of ketoprofen polar derivatives |